Abbott Laboratories (NYSE:ABT – Get Free Report) CEO Robert B. Ford sold 141,679 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the completion of the sale, the chief executive officer now owns 220,059 shares in the company, valued at $25,617,068.19. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Abbott Laboratories Stock Down 0.4 %
NYSE:ABT opened at $116.40 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.68 and a quick ratio of 1.18. The firm has a market cap of $202.49 billion, a PE ratio of 36.26, a price-to-earnings-growth ratio of 2.90 and a beta of 0.72. The company has a 50-day moving average of $109.24 and a 200 day moving average of $108.57. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.04. The firm had revenue of $10.38 billion during the quarter, compared to analysts’ expectations of $10.37 billion. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The company’s revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.08 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 4.66 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Abbott Laboratories
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in ABT. Unique Wealth Strategies LLC bought a new position in Abbott Laboratories in the second quarter worth about $28,000. Transcendent Capital Group LLC purchased a new stake in Abbott Laboratories during the fourth quarter valued at approximately $29,000. Richardson Financial Services Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $29,000. Redmont Wealth Advisors LLC purchased a new position in Abbott Laboratories in the first quarter worth $30,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $32,000. 75.18% of the stock is owned by institutional investors.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
See Also
- Five stocks we like better than Abbott Laboratories
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Are Penny Stocks a Good Fit for Your Portfolio?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What Is WallStreetBets and What Stocks Are They Targeting?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.